Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Oct;35(10):2078–2084. doi: 10.1128/aac.35.10.2078

Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children.

G L Kearns 1, M D Reed 1, R F Jacobs 1, M Ardite 1, R D Yogev 1, J L Blumer 1
PMCID: PMC245329  PMID: 1759830

Abstract

Ceftibuten (CFB), a new broad-spectrum cephalosporin for oral administration, possesses potent activity in vitro against a wide range of gram-negative and certain gram-positive pathogens frequently encountered in pediatric patients. Its antimicrobial spectrum and dosage formulation suggest a use for CFB in the treatment of otitis media and upper and lower respiratory and urinary tract infections in infants and children. To assess the pharmacokinetic characteristics of CFB in pediatric patients, we completed a multicenter investigation of 49 children (26 females) between the ages of 6 months and 17 years who had normal hepatic and renal functions and no evidence of chronic disease. Pharmacokinetic parameters were determined from repeated blood samples (n = 12) and, when possible, quantitative urine collections (n = 7) obtained over a 12- to 24-h period following a single oral CFB dose of either 4.5 or 9.0 mg/kg of body weight. CFB was quantitated from plasma and urine samples by using a sensitive, microanalytical high-pressure liquid chromatography method. The drug was rapidly absorbed (mean time to maximum concentration in serum = 140 min) and produced apparent peak concentrations in plasma (Cmax) ranging from 5.0 to 19.0 mg/liter. Average CFB pharmacokinetic parameters (+/- standard deviations) were as follows: apparent elimination half-life, 2.0 +/- 0.5 h; mean residence time, 3.9 +/- 1.1 h; apparent steady-state volume of distribution, 0.4 +/- 0.2 liter/kg; and apparent total plasma clearance (CL/F), 2.5 +/- 0.9 ml/min/kg. No significant differences in any of the pharmacokinetic parameters were observed between the two dosing groups. Significant (P < 0.05) negative correlations were found between patient age and CFB elimination half-life and CL/F and between the estimated creatinine clearance and renal clearance and CL/F. Apparent age dependence of CFB disposition was also reflected by a greater CL/F in children from 0.5 to less than or equal 5 years of age (3.1 +/- 1.1 ml/min/kg) than in children > 10 years of age (2.0 +/- 0.6 ml/min/kg; P < 0.005). The increased CL/f for CFB (3.0 +/- 0.5 ml/min/kg) was corroborated by a validation study performed with 11 infants (1.0 +/- 0.5 ml/min/kg) with CL/F for 19 subjects suggested that appreciable nonrenal clearance (1.3 +/- 0.6 ml/min/kg) of CFB occurred in children, a finding different from preliminary data for adults.

Full text

PDF
2078

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dunne A. JANA: a new iterative polyexponential curve stripping program. Comput Methods Programs Biomed. 1985 Aug;20(3):269–275. doi: 10.1016/0169-2607(85)90085-9. [DOI] [PubMed] [Google Scholar]
  2. Hayton W. L., Stoeckel K. Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet. 1986 Jan-Feb;11(1):76–86. doi: 10.2165/00003088-198611010-00005. [DOI] [PubMed] [Google Scholar]
  3. Jacobs R. F., Trang J. M., Kearns G. L., Warren R. H., Brown A. L., Underwood F. L., Kluza R. B. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. J Pediatr. 1985 Jun;106(6):1001–1007. doi: 10.1016/s0022-3476(85)80258-4. [DOI] [PubMed] [Google Scholar]
  4. Kearns G. L., Jacobs R. F., Thomas B. R., Darville T. L., Trang J. M. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates. J Pediatr. 1989 Mar;114(3):461–467. doi: 10.1016/s0022-3476(89)80573-6. [DOI] [PubMed] [Google Scholar]
  5. Kearns G. L., Reed M. D. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet. 1989;17 (Suppl 1):29–67. doi: 10.2165/00003088-198900171-00005. [DOI] [PubMed] [Google Scholar]
  6. Morselli P. L. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet. 1989;17 (Suppl 1):13–28. doi: 10.2165/00003088-198900171-00004. [DOI] [PubMed] [Google Scholar]
  7. Nakashima M., Uematsu T., Takiguchi Y., Mizuno A., Iida M., Yoshida T., Yamamoto S., Kitagawa K., Oguma T., Ishii H. Phase I clinical studies of 7432-S, a new oral cephalosporin: safety and pharmacokinetics. J Clin Pharmacol. 1988 Mar;28(3):246–252. doi: 10.1002/j.1552-4604.1988.tb03140.x. [DOI] [PubMed] [Google Scholar]
  8. Schwartz G. J., Brion L. P., Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987 Jun;34(3):571–590. doi: 10.1016/s0031-3955(16)36251-4. [DOI] [PubMed] [Google Scholar]
  9. Shawar R., LaRocco M., Cleary T. G. Comparative in vitro activity of ceftibuten (Sch 39720) against bacterial enteropathogens. Antimicrob Agents Chemother. 1989 May;33(5):781–784. doi: 10.1128/aac.33.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Steele R. W., Kearns G. L. Antimicrobial therapy for pediatric patients. Pediatr Clin North Am. 1989 Oct;36(5):1321–1349. doi: 10.1016/s0031-3955(16)36770-0. [DOI] [PubMed] [Google Scholar]
  11. WAGNER J. G., NELSON E. Per cent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci. 1963 Jun;52:610–611. doi: 10.1002/jps.2600520629. [DOI] [PubMed] [Google Scholar]
  12. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978 Dec;6(6):547–558. doi: 10.1007/BF01062109. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES